These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11302493)

  • 1. UCF76 compounds, new inhibitors of farnesyltransferase produced by Streptomyces.
    Hara M; Soga S; Shono K; Eishima J; Mizukami T
    J Antibiot (Tokyo); 2001 Feb; 54(2):182-6. PubMed ID: 11302493
    [No Abstract]   [Full Text] [Related]  

  • 2. UCF116, new inhibitors of farnesyltransferase produced by Streptomyces.
    Hara M; Soga S; Itoh M; Shono K; Eishima J; Mizukami T
    J Antibiot (Tokyo); 2000 Jul; 53(7):720-3. PubMed ID: 10994815
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Sattler I
    Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Imidazolylmethylaminophenylsulfonyltetrahydroquinolines, a novel series of farnesyltransferase inhibitors.
    Ding CZ; Hunt JT; Ricca C; Manne V
    Bioorg Med Chem Lett; 2000 Feb; 10(3):273-5. PubMed ID: 10698452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and characterization of piperazinedione-based dual protein inhibitors for both farnesyltransferase and geranylgeranyltransferase-I.
    Qiao Y; Gao J; Qiu Y; Wu L; Guo F; Lo KK; Li D
    Eur J Med Chem; 2011 Jun; 46(6):2264-73. PubMed ID: 21440964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
    Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of tripeptidyl farnesyltransferase inhibitors.
    Lee HY; Sohn JH; Kwon BM
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1599-602. PubMed ID: 12039571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Farnesyltransferase inhibitors.
    Adjei AA
    Cancer Chemother Biol Response Modif; 2002; 20():151-67. PubMed ID: 12703204
    [No Abstract]   [Full Text] [Related]  

  • 10. 3-Aryl-4-aryloyl-1-(1H-imidazol-5-yl)methylpyrrole, a novel class of farnesyltransferase inhibitors.
    Lee H; Lee J; Shin Y; Jung W; Kim JH; Park K; Ro S; Chung HH; Koh JS
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2963-5. PubMed ID: 11677136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo.
    Wiesner J; Kettler K; Sakowski J; Ortmann R; Katzin AM; Kimura EA; Silber K; Klebe G; Jomaa H; Schlitzer M
    Angew Chem Int Ed Engl; 2004 Jan; 43(2):251-4. PubMed ID: 14695623
    [No Abstract]   [Full Text] [Related]  

  • 12. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors.
    Sebti SM; Der CJ
    Nat Rev Cancer; 2003 Dec; 3(12):945-51. PubMed ID: 14737124
    [No Abstract]   [Full Text] [Related]  

  • 13. Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.
    Dinsmore CJ; Bogusky MJ; Culberson JC; Bergman JM; Homnick CF; Zartman CB; Mosser SD; Schaber MD; Robinson RG; Koblan KS; Huber HE; Graham SL; Hartman GD; Huff JR; Williams TM
    J Am Chem Soc; 2001 Mar; 123(9):2107-8. PubMed ID: 11456854
    [No Abstract]   [Full Text] [Related]  

  • 14. Design, synthesis and early structure-activity relationship of farnesyltransferase inhibitors which mimic both the peptidic and the prenylic substrate.
    Schlitzer M; Böhm M; Sattler I; Dahse HM
    Bioorg Med Chem; 2000 Aug; 8(8):1991-2006. PubMed ID: 11003144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RPR 130401, a nonpeptidomimetic farnesyltransferase inhibitor with in vivo activity.
    Vrignaud P; Bissery MC; Mailliet P; Lavelle F
    Ann N Y Acad Sci; 1999; 886():249-51. PubMed ID: 10667231
    [No Abstract]   [Full Text] [Related]  

  • 16. Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I.
    Bergman JM; Abrams MT; Davide JP; Greenberg IB; Robinson RG; Buser CA; Huber HE; Koblan KS; Kohl NE; Lobell RB; Graham SL; Hartman GD; Williams TM; Dinsmore CJ
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1411-5. PubMed ID: 11378366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of homofarnesoyl-substituted CAAX-peptidomimetics as farnesyltransferase inhibitors and antiproliferative agents.
    Schlitzer M; Sattler I; Dahse HM
    Bioorg Med Chem; 1999 Sep; 7(9):2037-45. PubMed ID: 10530953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CAAX peptidomimetics: their farnesyltransferase inhibition activity and antitumor effect].
    Ohkanda J
    Seikagaku; 2002 Jan; 74(1):46-50. PubMed ID: 11889772
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors.
    Schlitzer M
    Curr Pharm Des; 2002; 8(19):1713-22. PubMed ID: 12171543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.